ID   COLO 320HSR
AC   CVCL_0220
SY   COLO-320HSR; COLO #320HSR COLO320HSR; COLO 320 HSR; COLO-320-HSR; COLO 320 (HSR); COLO-HSR; Colorado 320 Homogeneously Staining Regions
DR   CLO; CLO_0002547
DR   CLO; CLO_0009960
DR   EFO; EFO_0002137
DR   MCCL; MCC:0000109
DR   CLDB; cl832
DR   CLDB; cl833
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-220.1
DR   BCRC; 60109
DR   BioGRID_ORCS_Cell_line; 847
DR   BioSample; SAMN03473155
DR   cancercelllines; CVCL_0220
DR   Cell_Model_Passport; SIDM00842
DR   ChEMBL-Cells; CHEMBL3308337
DR   ChEMBL-Targets; CHEMBL2366265
DR   ColonAtlas; COLO320HSR
DR   Cosmic; 720341
DR   Cosmic; 808508
DR   Cosmic; 910569
DR   Cosmic; 1609506
DR   Cosmic; 1995369
DR   Cosmic-CLP; 910569
DR   DepMap; ACH-002219
DR   ECACC; 87101501
DR   EGA; EGAS00001000978
DR   GDSC; 910569
DR   GEO; GSM206462
DR   GEO; GSM274778
DR   GEO; GSM784008
DR   GEO; GSM843491
DR   GEO; GSM1448182
DR   GEO; GSM1669685
DR   IARC_TP53; 21232
DR   IGRhCellID; COLO320HSR
DR   KCLB; 10220.1
DR   LINCS_LDP; LCL-1189
DR   PharmacoDB; COLO320HSR_223_2019
DR   PRIDE; PXD005235
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0220
DR   PubChem_Cell_line; CVCL_0220
DR   TOKU-E; 986
DR   Wikidata; Q54814091
RX   PubMed=498117;
RX   PubMed=3164477;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25877200;
RX   PubMed=25926053;
RX   PubMed=27397505;
RX   PubMed=28854368;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); ClinVar=VCV002203685; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=2.14%; East Asian, North=0.47%; East Asian, South=2.14%; South Asian=10.52%; European, North=6.29%; European, South=78.44% (PubMed=30894373).
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
ST   Source(s): ATCC; Cosmic-CLP; KCLB; PubMed=25877200; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 15
ST   D21S11: 31,33.2
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 13
ST   FGA: 20
ST   Penta D: 9,12
ST   Penta E: 11,13
ST   TH01: 8,9
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0219 ! COLO 320DM
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=498117;
RA   Quinn L.A., Moore G.E., Morgan R.T., Woods L.K.;
RT   "Cell lines from human colon carcinoma with unusual cell products,
RT   double minutes, and homogeneously staining regions.";
RL   Cancer Res. 39:4914-4924(1979).
//
RX   PubMed=3164477; DOI=10.1073/pnas.85.13.4804;
RA   Von Hoff D.D., Needham-VanDevanter D.R., Yucel J., Windle B.E.,
RA   Wahl G.M.;
RT   "Amplified human MYC oncogenes localized to replicating submicroscopic
RT   circular DNA molecules.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4804-4808(1988).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//